// App-Quantinova.ai

1146 : Enhancer of zeste homolog 2 (EZH2) inhibition in metastatic melanoma promotes tumor regression in vivo

Researchers

Presenter

  • Deepanwita Sengupta

Principal Investigators

  • Nathan Avaritt

  • Sara C. Shalin

  • Alan J. Tackett

Medical Centers

  • UAMS, Little Rock, AR.

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Melanoma

  • Skin carcinoma

  • Solid malignancies

Biomarkers

  • Enhancer of zeste homolog 2

Drug/Treatment

  • EZH2

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved